JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, T. R.
Right arrow Articles by Grigsby, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, T. R.
Right arrow Articles by Grigsby, P. W.
Journal of Nuclear Medicine Vol. 44 No. 2 192-197
© 2003 by Society of Nuclear Medicine


Clinical Investigations

Improved Prognostic Value of 18F-FDG PET Using a Simple Visual Analysis of Tumor Characteristics in Patients with Cervical Cancer

Tom R. Miller, MD, PhD1, Edward Pinkus, MD1, Farrokh Dehdashti, MD1 and Perry W. Grigsby, MD2

1 Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
2 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri

In patients with cervical cancer, it is important to estimate prognosis at the time of diagnosis. This study using PET with 18F-FDG was undertaken to determine whether a simple and fast visual analysis of characteristics of the primary tumor before initiation of treatment could achieve this goal. Methods: Forty-seven patients with cervical cancer who were to be treated by combined radiation therapy and chemotherapy were imaged before beginning treatment. They were then followed for up to 3 y for evidence of recurrence or death. Images of the chest, abdomen, and pelvis were obtained 40–90 min after administration of 370–555 MBq (10–15 mCi) 18F-FDG. Three observers then independently graded the primary tumor for size (0 = small, 1 = moderate, 2 = large), shape (0 = spherical, 1 = nonspherical), heterogeneity of uptake (0 = none, 1 = moderate, 2 = marked), and presence of lymph nodes (0 = none, 1 = pelvic, 2 = paraaortic, 3 = distant). The scores were summed to achieve a total score. A statistical calculation demonstrated that a score cutoff of 4 best separated patients with a good prognosis from patients with a bad prognosis. Kaplan-Meier analysis was used to compute progression-free survival and overall survival. Evaluation of lymph nodes alone was compared with the grading of tumor characteristics. Results: Observers 1 and 2 scored 26 patients as having a good prognosis and 21 as having a bad prognosis. Observer 3 scored 30 and 17, respectively, a statistically insignificant difference. Survival curves were almost identical for the 3 observers. For progression-free survival, approximately 12% of patients with a good score had disease recurrence whereas approximately 75% with a bad score had disease recurrence. For overall survival, approximately 10% (good) and 80% (bad) died. Evaluation of lymph nodes also separated the groups, but not as well as did visual analysis alone. The combination of the 2 was only slightly superior to visual assessment alone. Conclusion: A simple, rapid, and highly reproducible system is described for visual grading of characteristics of the primary tumor in patients with cervical cancer at the time of diagnosis. This approach separates patients with a poor prognosis from those who will do well, thus providing a new tool for accurate estimation of prognosis.

Key Words: PET • cervical cancer • 18F-FDG




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. A. Kidd and P. W. Grigsby
Intratumoral Metabolic Heterogeneity of Cervical Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5236 - 5241.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. M. Schuetze, L. H. Baker, R. S. Benjamin, and R. Canetta
Selection of Response Criteria for Clinical Trials of Sarcoma Treatment
Oncologist, April 1, 2008; 13(suppl_2): 32 - 40.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. A.D. Smith, R. I. Sharma, A. M. Thompson, and F. E.M. Paulin
Tumor 18F-FDG Incorporation Is Enhanced by Attenuation of P53 Function in Breast Cancer Cells In Vitro
J. Nucl. Med., September 1, 2006; 47(9): 1525 - 1530.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al.
Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas
J. Nucl. Med., March 1, 2006; 47(3): 419 - 425.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Hooft, A. A. M. van der Veldt, P. J. van Diest, O. S. Hoekstra, J. Berkhof, G. J. J. Teule, and C. F. M. Molthoff
[18F]Fluorodeoxyglucose Uptake in Recurrent Thyroid Cancer Is Related to Hexokinase I Expression in the Primary Tumor
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 328 - 334.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. K. Buck, G. Glatting, and S. N. Reske
Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker?
J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276.
[Full Text] [PDF]


Home page
JNMHome page
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto
In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma
J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.